{
    "clinical_study": {
        "@rank": "109373", 
        "arm_group": {
            "arm_group_label": "SAF-301", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "P2-SAF-301 is an open-label interventional study without administration of investigational\n      product, evaluating the long-term safety and tolerability of intracerebral SAF-301\n      previously administered to 4 patients with Sanfilippo type A syndrome.\n\n      The primary objective is to collect additional safety and tolerability data on intracerebral\n      SAF-301 previously administered to 4 patients with Sanfilippo type A syndrome.\n\n      The secondary objective is to further collect data to assess the effects of SAF-301 on\n      neurological and psychological status, and potential biological markers."
        }, 
        "brief_title": "Long-term Follow-up of Sanfilippo Type A Patients Treated by Intracerebral SAF-301 Gene Therapy", 
        "condition": [
            "Mucopolysaccharidosis Type III A", 
            "Sanfilippo Disease Type A"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Mucopolysaccharidoses", 
                "Mucopolysaccharidosis III"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients having completed the previous phase I/II study (P1-SAF-301),\n\n          -  Family understanding the follow-up procedures and the informed consent,\n\n          -  Patient's parents having signed the informed consent form.\n\n        Exclusion Criteria:\n\n          -  Participation in any other clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02053064", 
            "org_study_id": "P2-SAF-301"
        }, 
        "intervention": {
            "arm_group_label": "SAF-301", 
            "intervention_name": "SAF-301", 
            "intervention_type": "Genetic"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Neurodegenerative diseases", 
            "Nervous systems diseases", 
            "Genetic diseases, Inborn", 
            "Metabolic diseases", 
            "Gene therapy", 
            "Adeno Associated Virus (AAV)"
        ], 
        "lastchanged_date": "January 31, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Le Kremlin-Bic\u00eatre", 
                    "country": "France", 
                    "zip": "94275"
                }, 
                "name": "H\u00f4pitaux Universitaires Paris Sud (Bic\u00eatre)"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Long-term Follow-up of Patients With Sanfilippo Type A Syndrome Who Have Previously Been Treated in the P1-SAF-301 Clinical Study Evaluating the Tolerability and Safety of the Intracerebral Administration of SAF-301.", 
        "overall_official": {
            "affiliation": "AP-HP H\u00f4pital Bic\u00eatre", 
            "last_name": "Kumaran DEIVA, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: ANSM - Agence National de S\u00e9curit\u00e9 du M\u00e9dicament", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Checking of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "until 32 months after SAF-301 administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02053064"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Information on neurological and cognitive changes based on clinical status, standardized neurocognitive and behavioral assessments", 
                "safety_issue": "No", 
                "time_frame": "2 years after the injection of SAF-301"
            }, 
            {
                "measure": "Information on changes in potential biomarkers of the disease", 
                "safety_issue": "No", 
                "time_frame": "2 years after the injection of SAF-301"
            }, 
            {
                "measure": "Information to further evaluation of immune response", 
                "safety_issue": "No", 
                "time_frame": "2 years after the injection of SAF-301"
            }
        ], 
        "source": "LYSOGENE", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LYSOGENE", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}